We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
California-based biopharmaceutical company MediciNova Inc. and Zhejiang Medicine Co., a Chinese pharmaceutical manufacturer, have announced a joint venture to develop and commercialize MediciNova’s MN-221 in China
